OTCM
ANTH
Market cap2kUSD
Oct 08, Last price
0.00USD
1Q
9,900.00%
Jan 2017
-100.00%
IPO
-100.00%
Name
Anthera Pharmaceuticals Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-79.05%
Revenues
0
Net income
0
CFO
0
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Anthera Pharmaceuticals, Inc., a biopharmaceutical enterprise, concentrates on developing and commercializing therapeutic solutions for conditions with significant unmet medical needs. The company's pipeline includes Sollpura, an investigational non-porcine pancreatic enzyme replacement therapy in Phase III clinical trials for individuals with exocrine pancreatic insufficiency. It is also advancing Blisibimod, currently in Phase II clinical evaluation for B-cell mediated autoimmune diseases, such as immunoglobulin A nephropathy (IgA nephropathy). Anthera holds licensing agreements with Amgen, Inc. and Eli Lilly and Company. Founded in 2004, the company's base of operations is in Houston, Texas.
Key people
Paul Truex
Executive Chairman of the Board · since 2016
J. Craig Thompson
President, Chief Executive Officer, Director · since 2016
May Liu
Senior Vice President - Finance and Administration, Principal Accounting Officer · since 2013
Brent Furse
Independent Director · since 2016
Christopher Henney
Independent Director · since 2016
Independent Director · since 2014
Philip Sager
Independent Director · since 2014
David Thompson
Independent Director · since 2005
Legal address
C/O Corporation Service Company
251 Little Falls Drive
Wilmington, DE 19808
US
251 Little Falls Drive
Wilmington, DE 19808
US
Headquarters
25801 Industrial Boulevard
Suite B
Hayward, CA 94545
US
Suite B
Hayward, CA 94545
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||